[1] | Sharukho GV, Zolotareva M.Yu., Feshchenko I.P. "On the prevention of noncommunicable diseases associated with the food factor in the population. Tyumen region "// Public health services of the Russian Federation 2014, T.58, №4, C 54-56. |
[2] | Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384(9943): 626-35. |
[3] | Jacome – Sose V.V., Parks E. J. Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans. Curr. Opin. Lipidol. 2014; 25 (3): 213 – 20. |
[4] | Petrov NA, Morozov, SA, Pak K.K. "Cholesterolemia and non-infectious diseases" N. Novgorod 2014, p.216. |
[5] | Salazar M.R., Carbajal H.A., Espeshe W.G., Leiva Sisnieguez C.E., March C.E., Balbin E. et al. Comparison of the abilities of the plasma triglyceride/high – density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. DiabVasc. Dis. Res. 2013; 10 (4): 346 – 52. |
[6] | Titov V.N. "Etiology and pathogenesis of sequential development of tests of hypertriglyceridemia, hypercholesterolemia and hyperglycaemia. The generality of the etiological factors of metabolic pandemics and the complexing role of apos-III "// Clinical laboratory diagnostics, 2016, No. 1, Vol. 61, p. 4-12. |
[7] | Tenenbaum A., Klempfner R., Fisman E.Z. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc. Diabetol. 2014; 13: 159 – 64. |
[8] | Phan B.A., Toth P.P. Dyslipidemia in women: etiology and management. Int. J. Womens Health. 2014; 4 (6): 185 – 94. |
[9] | Pogozheva A.V. "Modern approaches to non-expert correction of hypercholesterolemia" // Cardiology-2010, Т.50, №4, p. 86-91. |
[10] | Brewer H.B., Santamarina – Fojo S.M., Hoeg J.M. Genetic dyslipoproteinemias. Ch. 5. Atheroselerosis and Coronary Artery Disease. Ed. by F.R. Ross. 2006: 69 – 84. |
[11] | Yashchin KL, Titov VV, Mazur SV "Chronic non-infectious diseases and their risk factors: prospects for prevention" // Novosibirsk - 2014, p. 378. |
[12] | Olsson A.G., S.Plath, Feageman O. et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)//Carculation 2008; 1452-1460. |
[13] | Makhov SS, Barisov AA "Endocrinology" - Cf. Petersburg - 2013, p. 432. |
[14] | Sukhanov AV, Denisova DV "Association of levels of lipid fractions with the state of cognitive functions in adolescence" / / Pediatrics. Journal of G.N. Speranskogo 2013, T.92, p. 146-152. |
[15] | Law M., Wald N., Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta – analysis. BMJ. – 2013. 326 (7404) 1423. |
[16] | Kuchmin AN, Chernov SA, Teslya A.N., etc. "Resistant hypercholesterolemia in clinical practice: a new look at the causes and possible ways of treatment" // Military Medical Journal, 2010, Vol.331, No. 11, p. 25-30. |
[17] | Smirnov GP, Mal'shev PP "Differential diagnostics of high hypercholesterolemia" // Atherosclerosis and dyslipidemia 2012: 2: 36-38. |
[18] | Williams R.R., Schumacher M.C., Barlow G.K. et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah Am J Cardiol 2006: 72: 18D – 24D. |
[19] | Osochuk MA, Butorova LI, Soledenkoho KS, Tokmulen GM, etc. "Modern approaches to the treatment of hypercholesterolemia in patients with ischemic heart disease combined with metabolic syndrome and chronic non-alcoholic steatohepatitis" / / Russian Cardiology Journal, 2014, 7, p. 105-109. |
[20] | Stone NJ. Robinson J. Lichtenstein AH. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology – American Heart Association Task Force on Practice Guidelines Carculation 2013. |
[21] | Kuznetsov I.V. "Modern strategy of hypercholesterolemia treatment" // Scientifik Journal "Science Rise" №3 / 4 (8) 2015. |
[22] | Solijanlahti S., Raininko R., Hyttinen L., Lauerma K., Keto P., Vuorio A.F., Autti T. Statin – treated familial hypercholesterolemia patients with coronary heart disease and pronounced atherosclerosis do not have more brain lesions than healthy controls in later middle age. ActaRadiol. 2011: 48(8): 894 – 9. |
[23] | Khlebtsova EB, Turtsenkov SS, Baysultanov I.Kh., Sorokina A.A. "Influence of the lymphantanisic on hypercholesterolemia" // Pharmacia 2014, No. 8, p. 23-26. |
[24] | Zubareva M., Rozhkova T., Gornyakova N., Solovieva E. et al. "Efficacy, safety and tolerability of rosuvastatin therapy in patients with very high cardiovascular risk with primary hypercholesterolemia" / / Phys. 2012, №2, p. 61-64. |
[25] | Schuster H. Barter P., Stender S et al Ettects of switching statins on achievement of lipid goals Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study//Am Heart J – 2014: 147:705 – 12. |
[26] | Nechaeva GI, Tereshchenko Yu. V. "Prevention of lipid abnormalities" / / The attending physician - 2010-7, p. 56-58. |
[27] | Kearly P. Heart Protection Study Collaborative Group. Cost – effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20536 individuals//Lancet. 2009 365: 1779 – 1785. |
[28] | Korneva VA, Kuznetsova T. Yu., Tikhova G.P. "The value of the definition of lipoprotein (A) as an additional marker of cardiovascular risk in patients with familial hypercholesterolemia." // Russian Cardiology Journal 2016, No. 6, p. 45-49. |
[29] | Bos S, Duvekot MH, Touw – Blommesteijn AC, et al. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin – treated patients with familial hypercholesterolemia. Atherosclerosis. 2015 Jul 14; 242(1): 226 – 9. |
[30] | Kukharchuk VV, Malyshev PP, Meshkov AN. "Family Hypercholesteremia: Modern Aspects of Diagnosis, Prevention and Therapy" // Cardiology 1, 2009. |
[31] | Koivisto U.-M., Turtola H., Aalto-Setala K. et al. The familial hypercho- lesterolemia (FH) – North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland//J.Clin. Invest. 2011, V.90, №1, P. 219-228. |
[32] | Kassner U, Schlabs T, Rosada A, et al. Lipoprotein (a) – An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015 May; 18: 263 – 7. |
[33] | Wiegman A, Gidding SS, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; May 25: 1 – 17. |
[34] | Mabuchi H., Miyamoto S., Ueda K., Oota M., Takegoshi T., Wakasugi T. et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis. 2012, 61 (1): 1-6. |
[35] | Rozhkova TA, Mal'shev PP, Zubareva M.Yu.36. Nordestgaard BG, Chapman MJ. Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as cardiovascular risk factor: Current status. Eur. Heart J. 2010; 31: 2844 – 53. |
[36] | Nordestgaard BG, Chapman MJ. Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as cardiovascular risk factor: Current status. Eur. Heart J. 2010; 31: 2844 – 53. |
[37] | Hopkins PN, Toth HH, Ballantyne CM, Rader DJ, Familial Hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J ClinLipidol. – 2011; 5 (3 suppl): S9-17. |
[38] | Stone N.J., Robinson J.G., Lichtenstein A. H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce athcrosclerotic cardiovascular risk in aduits: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (suppl 2): S1-45. |
[39] | Polupanov AG, Khalmatov AN, Altymysheva AT, etc. "The prevalence of cardiovascular risk factors among the residents of the Kyrgyz Republic of working age (according to the international study "INTEREPID") Part III. Prevalence of Metabolic Risk Factors Central Asian Medical Journal 2013, 4: 213-220. |
[40] | Lioyd – Jones D., Adams R., Carnethon M. et al. Fleart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119 (3): 480 – 486. |
[41] | Muromiseva G. A., Kontsevaya A. V., Konstantinov V. V. et al. The prevalence of non – infectious diseases risk factors in Russian population in 2012 – 2013 years. The results of FCVD – RF. Cardiovascular Therapy and Prevention 2014: 13 (6): 4-11. Russian. |
[42] | Mohan I, Gupta R, Misra A, Sharma KK, Agrawal A, Vikram NK, et al. Disparities in Prevalence of Cardiometablic Risk Factors in Rural, Urban – Poor, and Urban – Middle Class Women in India. J Plos One. 2016; 11 (2): e 0149437. |
[43] | Berkinbaev SF, Musagalieva AT, et al. Risk factors for the development of cardiovascular diseases among the rural population according to the 2014 screening data. honey. № 3, p. 54-57 |
[44] | Samorodskaya I.V., Bolotova E.V., Timofeeva Yu.K. "The prevalence of risk factors and programs for the prevention of cardiovascular diseases among the rural population" // Prophylactic medicine 6, 2016, art.21- 25. |
[45] | Voyevoda MI, Kovalkova NA, Ragino Yu. I., Travnikova N. Yu. et all. "The prevalence of the metabolic syndrome among the inhabitants of Novosibirck at the age of 25 to 45 years" // Therapeutic archive 10, 2016, art. 51-56. |
[46] | Boytsov SA, Deev AD, Shalnova SA. "Mortality and risk factors for the development of non-communicable diseases in Russia: features, dynamics, prognosis" // Therapeutic Archive 01, 2017, p. 5-13. |
[47] | Babintseva Ya.D., Camon L., Chepmen D., Lomm M., et all. "Biological activity of high-density lipoprotein fractions and their role in the development of cardiovascular diseases" // Therapeutic Archives 9, 2016, p. 111-11848. Tall AR, Yvan – Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015; 15: 104 – 116. |
[48] | Tall AR, Yvan – Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol.2015; 15: 104 – 116. |
[49] | Rodrigues AL, Ball J, Ski C, Stewart S, Carrington MJ. A systematic review and metaanalysis of primary prevention programmes to improve cardiometabolic risk in non-urban communities. J Preventive medicine 2016, №5, р. 17-26. |
[50] | Oliveira GB, Avezum A, Roever L, Cardiovascular Disease Burden: Evolving Knowledge of Risk Factors in Myocardial Infarction and Stroke through Population – Based Research and Perspectives in Global Prevention. J Frontiers in Cardiovascular Medicine. 2015; 13: 2: 32. |
[51] | Record NB, Onion DK, Prior RE, Dixon DC, Record SS, et.al. Communitywide cardiovascular disease prevention programs and health outcomes in a rural county, 1970 – 2010. J American Medical Association. 2015; 313(2): 147-155. |
[52] | Nicholls SJ, Kritharides L. Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road? J.AmCollCardiol. 2015; 65: 1296-1297. |
[53] | Meyer M, Cynthia K, Perry, Jasmin C, Sumrall C, et al. Physical Activity – Related Policy and Environmental Strategies to Prevent Obesity in Rural Communities: A Systematic Review of the Literature, 2002 – 2013. J Prev Chronic Disease. 2016; 1: 7: 13. |
[54] | Afanasyeva OA, Pilayeva EA, Klesareva EA et all. "Lipoprotein, autoantibodies to it and circulating subpopulations of T-lymphocytes as independent risk factors for coronary artery atherosclerosis" // Therapeutic Archives 9, 2016, art. 31-3855. |
[55] | Kumar R. Anthropometric and behavioral risk factor for non- communicable diseases: a cluster survey from rural Wardha. Indian Journal of Public Health. 2015; 59(1): 61 – 64. |
[56] | Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community programs for the prevention of cardiovascular disease: a systematic review of the literature. J American journal of Epidemiology. 2015; 172 (5): 501 – 516. |
[57] | Yejov M.V., Lazaeva O.V., Sagaydak V.A., et all. The frequency of lipid metabolism disorders and the use of statins in acute coronary syndrome (according to the Russian Federal Register of Acute Coronary Syndrome) "Atherosclerosis and Dyslipidemia" 01.2018, p. 47. |